from PR Newswire
Savient Pharmaceuticals to Hold Fourth Quarter and Year-End 2012 Financial Results Conference Call on Tuesday, March 19, 2013
February 26, 2013
from PR Newswire
Sobi and Savient Pharmaceuticals Announce Co-Promotion Agreement for Kineret® (anakinra) in the U.S.
February 19, 2013
from PR Newswire
Merger and Acquisition Activity Expected to Rise in 2013 as Big Pharma Companies Flush With Cash
January 23, 2013
- First approved therapy in the European Union to address a significant unmet medical need for patients with chronic tophaceous gout Read More
from PR Newswire
Savient Pharmaceuticals Announces the Election of Genzyme CEO Dr. David Meeker to Its Board of Directors
January 08, 2013
from PR Newswire
Savient Pharmaceuticals to Present at the 31st Annual J.P. Morgan Healthcare Conference
January 04, 2013
from PR Newswire
Perfect Trade Setups, How to Play STP, AZZ, SVNT and IDIX
January 02, 2013
Our Pros Knew X, SVNT, FRO and DANG Would Be Top Gainers on Friday
December 17, 2012
from PR Newswire
New Data Demonstrate KRYSTEXXA®-Treated Refractory Chronic Gout Patients Experienced Significantly Improved Health-Related Quality of Life
November 13, 2012
Post-Hoc Analyses Examining HRQOL, Tophus Reduction and Infusion Reaction Mitigation Presented at the 2012 ACR/ARHP Annual Meeting Read More
from PR Newswire
Biotech Industry Skyrockets in 2012 as FDA Approval Rate Increases
November 12, 2012
New Data Published in Annals of the Rheumatic Diseases Confirm Long-Term Safety and Efficacy of KRYSTEXXA® for the Treatment of Refractory Chronic Gout
November 12, 2012
Two Supportive Posters Presented at the ACR/AHRP Annual Meeting Also Demonstrate Positive Safety and Efficacy Outcomes from the KRYSTEXXA Open-Label Extension Study Read More
from PR Newswire
Savient Pharmaceuticals Reports Third Quarter 2012 Financial Results
November 08, 2012
from PR Newswire
Savient Pharmaceuticals to Hold Third Quarter 2012 Financial Results Conference Call on Thursday, November 8, 2012
October 25, 2012
from PR Newswire
If Granted a Marketing Authorization, KRYSTEXXA Will Address a Significant Unmet Need for Certain Patients with Refractory Chronic Gout in the European Union Read More
from PR Newswire
Biotech Industry Looks to Benefit as FDA Speeds Up Process for Drugs for Critical Diseases
October 16, 2012
Savient Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
September 26, 2012
from PR Newswire
Savient Pharmaceuticals Names John P. Hamill Chief Financial Officer
September 24, 2012
from PR Newswire
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here